Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Abstract
Anticancer therapy has always been a vital challenge for the development of nanomedicine. Repeated single therapeutic agent may lead to undesirable and severe side effects, unbearable toxicity and multidrug resistance due to complex nature of tumor. Nanomedicine-based combination anticancer therapy can synergistically improve antitumor outcomes through multiple-target therapy, decreasing the dose of each therapeutic agent and reducing side effects. There are versatile combinational anticancer strategies such as chemotherapeutic combination, nucleic acid-based co-delivery, intrinsic sensitive and extrinsic stimulus combinational patterns. Based on these combination strategies, various nanocarriers and drug delivery systems were engineered to carry out the efficient co-delivery of combined therapeutic agents for combination anticancer therapy. This review focused on illustrating nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs for synergistically improving anticancer efficacy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Conventional strategy is to inhibit expression or activity of drug resistance-associated genes through siRNA or chemical inhibitors.
“The conventional strategy is to inhibit the expression or activity of these genes through small interfering RNA (siRNA) or chemical inhibitors [135–137].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [137]
The citation lists haven’t been fetched yet
References 201 · Cited by 77
- Authors
- Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of Utah (US)
- Corresponding author
- Gao, Zhonggao
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 115
- Pages
- 82-97
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2626848319
- Cited by
- 77
- References
- 201
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 11 · 2022: 9 · 2021: 6 · 2020: 21 · 2019: 9 · 2018: 7 · 2017: 1
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81373342)
- Scientific Research Foundation for Young Scholar of Peking Union Medical College
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- combination cancer therapy, nucleic acids, small molecule drugs, co-delivery, nanocarriers, drug delivery systems, multidrug resistance, synergistic antitumor effect, stimuli-responsive drug delivery
- MeSH terms
- Animals, Antineoplastic Agents, Delayed-Action Preparations, Drug Carriers, Drug Combinations, Drug Synergism, Humans, Neoplasms, Nucleic Acids, Nanomedicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
